Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Chromosomal Rearrangement”

112 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 112 results

Testing effectiveness (Phase 2)Looking for participantsNCT06249191
What this trial is testing

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell LymphomaHigh Grade B-Cell Lymphoma
OHSU Knight Cancer Institute 30
Testing effectiveness (Phase 2)Looking for participantsNCT06728410
What this trial is testing

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene RearrangementFGFR2 Gene Mutation
Mehmet Akce 38
Testing effectiveness (Phase 2)Study completedNCT04042558
What this trial is testing

A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies

Who this might be right for
NSCLC Stage IIIBNSCLC Stage IVEGFR Gene Mutation+2 more
Centre Francois Baclesse 150
Testing effectiveness (Phase 2)UnknownNCT04292119
What this trial is testing

Lorlatinib Combinations in Lung Cancer

Who this might be right for
Lung CancerAnaplastic Lymphoma Kinase Gene TranslocationROS1 Rearrangement+4 more
Massachusetts General Hospital 96
Testing effectiveness (Phase 2)Active Not RecruitingNCT03157128
What this trial is testing

Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

Who this might be right for
Non-Small Cell Lung CancerMedullary Thyroid CancerColon Cancer+1 more
Eli Lilly and Company 857
Not applicableLooking for participantsNCT05122806
What this trial is testing

Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC

Who this might be right for
Non-small Cell Lung CancerALK Gene Rearrangement Positive
Groupe Francais De Pneumo-Cancerologie 100
Early research (Phase 1)Looking for participantsNCT05681780
What this trial is testing

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

Who this might be right for
Non Small Cell Lung CancerStage IV Non-small Cell Lung CancerRecurrent Non Small Cell Lung Cancer
H. Lee Moffitt Cancer Center and Research Institute 20
Testing effectiveness (Phase 2)Ended earlyNCT05565794
What this trial is testing

Pemigatinib After Curative Local Therapy in Advanced iCCA With FGFR2 Fusion/Rearrangements

Who this might be right for
Intrahepatic CholangiocarcinomaFGFR2 Gene MutationFGFR2 Gene Rearrangement+1 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2
Not applicableStudy completedNCT03727477
What this trial is testing

Efficacy of Treatment Sequences in Patients With Non-small Cell Lung Cancer Receiving Lorlatinib

Who this might be right for
Non-small Cell Lung Cancer MetastaticALK Gene Rearrangement PositiveROS-1 Gene Rearrangement Positive
Intergroupe Francophone de Cancerologie Thoracique 291
Testing effectiveness (Phase 2)Ended earlyNCT03445000
What this trial is testing

ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung CancerNon-small Cell Lung Cancer MetastaticNon-small Cell Lung Cancer Recurrent
ETOP IBCSG Partners Foundation 14
Large-scale testing (Phase 3)Ended earlyNCT03656536
What this trial is testing

Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Who this might be right for
Unresectable CholangiocarcinomaMetastatic Cholangiocarcinoma
Incyte Corporation 167
Testing effectiveness (Phase 2)Active Not RecruitingNCT05202782
What this trial is testing

Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma Associated With Chronic InflammationEBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell Lymphoma, Not Otherwise Specified+16 more
Northwestern University
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Testing effectiveness (Phase 2)UnknownNCT03608007
What this trial is testing

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

Who this might be right for
Lung CancerROS1 Gene Rearrangement
Betta Pharmaceuticals Co., Ltd. 69
Not applicableStudy completedNCT02718651
What this trial is testing

Blood-based Identification and Monitoring of Patients With ALK-translocated Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
University of Aarhus 70
Testing effectiveness (Phase 2)WithdrawnNCT01854372
What this trial is testing

Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement.

Who this might be right for
Newly Diagnosed Diffuse Large B-Cell LymphomaIntermediate (Burkitt-Like) Lymphoma
The University of Texas Health Science Center at San Antonio
Testing effectiveness (Phase 2)Looking for participantsNCT05014464
What this trial is testing

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 90
Testing effectiveness (Phase 2)Study completedNCT03230318
What this trial is testing

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Who this might be right for
Intrahepatic CholangiocarcinomaCombined Hepatocellular and Cholangiocarcinoma
Basilea Pharmaceutica 148
Testing effectiveness (Phase 2)Looking for participantsNCT05727176
What this trial is testing

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

Who this might be right for
Advanced CholangiocarcinomaFGFR2 FusionsGene Rearrangement
Taiho Oncology, Inc. 120
Testing effectiveness (Phase 2)Looking for participantsNCT04988555
What this trial is testing

Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Who this might be right for
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more
Sumitomo Pharma America, Inc. 606
Load More Results
24